0000950170-25-064981 | 10-Q | XBRL Viewer

The following table summarizes the impact of accounts receivable reserves on the gross trade accounts receivable balances as of March 31, 2025 and December 31, 2024:


In thousands	March 31, 2025			December 31, 2024
Gross trade accounts receivable	$	118,677		$	133,072
Trade allowances		(10,517	)		(9,433	)
Chargebacks		(1,426	)		(1,360	)
Accounts receivable, net	$	106,734		$	122,279

Calculation of Net Loss and Number of Ordinary Shares Used to Compute Basic and Diluted Net Loss per Share

The calculation of net loss and the number of Ordinary Shares and ADSs used to compute basic and diluted net loss per Ordinary Share and ADS for the three months ended March 31, 2025 and 2024 are as follows:


	For the Three Months Ended March 31,
In thousands	2025			2024
Net loss—basic and diluted	$	(15,697	)	$	(9,953	)
Weighted average Ordinary Shares outstanding—basic and diluted		413,422			410,146
Loss per Ordinary Share—basic and diluted	$	(0.04	)	$	(0.02	)

Weighted average ADS outstanding—basic and diluted		20,671			20,507
Loss per ADS—basic and diluted	$	(0.76	)	$	(0.49	)

Anti-Dilutive Securities Not Included in the Computation of Net Loss per Share

For the three months ended March 31, 2025 and 2024, the following potentially dilutive securities were not included in the computation of net loss per share because the effect would be anti-dilutive or because performance criteria were not yet met for awards contingent upon such measures:


	For the Three Months Ended March 31,
In thousands of Ordinary Shares	2025		2024
Stock options		30,373		29,492
Restricted stock and restricted stock units		19,716		14,828

Estimated Fair Value of Assets and Liability

The following tables present information about the estimated fair value of the Company’s assets and liabilities as of March 31, 2025 and December 31, 2024, and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:


	March 31, 2025
In thousands	Total		Level 1		Level 2		Level 3
Asset:
U.S. Treasury Securities	$	162,337	$	162,337	$	—	$	—
Money Market Fund		82,132		82,132		—		—
Repo Securities		5,000		—		5,000		—
Total	$	249,469	$	244,469	$	5,000	$	-


	December 31, 2024
In thousands	Total		Level 1		Level 2		Level 3
Asset:
U.S. Treasury Securities	$	174,722	$	174,722	$	—	$	—
Money Market Fund		67,456		67,456		—		—
Repo Securities		5,000		—		5,000		—
Total	$	247,178	$	242,178	$	5,000	$	—

Schedule of Reportable Segment Loss Including Significant Reportable Segment Expenses

The table below is a summary of the reportable segment loss, including significant reportable segment expenses:


	For the Three Months Ended March 31,
In thousands	2025			2024
US product revenue, net	$	35,661		$	48,114
Europe product revenue, net		5,392			1,865
RoW product revenue, net		(18	)		5,177
Total product revenue, net		41,035			55,156
Licensing and royalty revenue		982			1,363
Total revenue, net		42,017			56,519
Less: Cost of goods sold		16,887			24,615
Gross margin		25,130			31,904
Operating expenses:
Selling		7,384			10,250
General and administrative		8,648			9,415
Research and development		2,042			2,217
Payroll and payroll related expense		19,484			18,387
Non-cash stock-based compensation expense		4,327			5,218
Total operating expenses		41,885			45,487
Operating loss		(16,755	)		(13,583	)
Interest income, net		2,872			3,383
Other income, net		253			1,545
Loss from operations before taxes		(13,630	)		(8,655	)
Provision for income taxes		(2,067	)		(1,298	)
Segment & consolidated net loss	$	(15,697	)	$	(9,953	)

Revenue Recognition

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Revenue Recognition

(7) Revenue Recognition

The Company sells VASCEPA principally to a limited number of major wholesalers, as well as selected regional wholesalers and specialty retail pharmacy providers in the U.S. and Europe, or collectively, its distributors or its customers, most of whom in turn resell VASCEPA to retail pharmacies for subsequent resale to patients and healthcare providers. Patients are required to have a prescription in order to purchase VASCEPA. In addition to distribution agreements with distributors, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s product.

Revenues from product sales are recognized when the distributor obtains control of the Company’s product, which occurs at a point in time, typically upon delivery to the distributor and in certain instances upon shipment. Payments from distributors are generally

received 45 days from the date of sale. The Company evaluates the creditworthiness of each of its distributors to determine whether revenues can be recognized upon delivery, subject to satisfaction of the other requirements, or whether recognition is required to be delayed until receipt of payment. The Company calculates gross product revenues generally based on the wholesale acquisition cost or list price that the Company charges its distributors for VASCEPA.

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from (a) trade allowances, such as invoice discounts for prompt pay and distributor fees, (b) estimated government and private payor rebates and chargebacks and discounts, such as Medicaid reimbursements, (c) reserves for expected product returns and (d) estimated costs of incentives that are offered within contracts between the Company and its distributors, health care providers, payors and other indirect customers relating to the Company’s sales of its product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the distributor) or as a current liability (if the amount is payable to a party other than a distributor). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.

Trade Allowances: The Company generally provides invoice discounts on VASCEPA sales to its distributors for prompt payment and fees for distribution services, such as fees for certain data that distributors provide to the Company. The payment terms for sales to distributors in the U.S. and Europe generally include a 2-3% discount for prompt payment while the fees for distribution services are based on contractual rates agreed with the respective distributors. Based on historical data, the Company expects its distributors to earn these discounts and fees and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.

Rebates, Chargebacks and Discounts: The Company contracts with Medicaid, Medicare, other government agencies and various private organizations, or collectively, Third-party Payors, so that VASCEPA will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. We have withdrawn from the Medicaid Drug Rebate program and the 340B drug pricing program effective October 1, 2024. The Company estimates the rebates, chargebacks and discounts it will provide to Third-party Payors and deducts these estimated amounts from its gross product revenues at the time the revenues are recognized. The Company estimates these reserves based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company estimates the rebates, chargebacks and discounts that it will provide to Third-party Payors based upon (i) the Company’s contracts with these Third-party Payors, (ii) the government-mandated discounts applicable to government-funded programs, (iii) information obtained from the Company’s distributors and (iv) information obtained from other third parties regarding the payor mix for VASCEPA. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

Product Returns: The Company’s distributors have the right to return unopened unprescribed VASCEPA during the 18-month period beginning six months prior to the labeled expiration date and ending 12 months after the labeled expiration date. The expiration date for VASCEPA 1-gram and 0.5-gram size capsules is currently four years and three years, respectively, after being converted into capsule form, which is the last step in the manufacturing process for VASCEPA and generally occurs within a few months before VASCEPA is delivered to distributors. The Company estimates future product returns on sales of VASCEPA based on (i) data provided to the Company by its distributors (including weekly reporting of distributors’ sales and inventory held by distributors that provided the Company with visibility into the distribution channel in order to determine what quantities were sold to retail pharmacies and other providers), (ii) information provided to the Company from retail pharmacies, (iii) data provided to the Company by a third-party data provider which collects and publishes prescription data, and other third parties, (iv) historical industry information regarding return rates for similar pharmaceutical products, (v) the estimated remaining shelf life of VASCEPA previously shipped and currently being shipped to distributors and (vi) contractual agreements intended to limit the amount of inventory maintained by the Company’s distributors. These reserves are recorded in

the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.

Other Incentives: Other incentives that the Company offers to indirect customers include co-pay mitigation rebates provided by the Company to commercially insured patients who have coverage for VASCEPA and who reside in states that permit co-pay mitigation programs. The Company’s co-pay mitigation program is intended to reduce each participating patient’s portion of the financial responsibility for VASCEPA’s purchase price to a specified dollar amount. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish its accruals for co-pay mitigation rebates. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company adjusts its accruals for co-pay mitigation rebates based on actual redemption activity and estimates regarding the portion of issued co-pay mitigation rebates that it estimates will be redeemed.

The following tables summarize activity in each of the net product revenue allowance and reserve categories described above for the three months ended March 31, 2025 and 2024:


In thousands	Trade Allowances			Rebates, Chargebacks and Discounts			Product Returns			Other Incentives			Total
Balance as of December 31, 2024	$	9,433		$	97,526		$	4,734		$	1,548		$	113,241
Provision related to current period sales		16,627			164,873			378			4,131			186,009
Provision related to prior period sales		—			(445	)		—			—			(445	)
Credits/payments made for current period sales		(6,461	)		(88,769	)		(50	)		(2,920	)		(98,200	)
Credits/payments made for prior period sales		(9,082	)		(93,205	)		(1,276	)		(1,645	)		(105,208	)
Balance as of March 31, 2025	$	10,517		$	79,980		$	3,786		$	1,114		$	95,397


In thousands	Trade Allowances			Rebates, Chargebacks and Discounts			Product Returns			Other Incentives			Total
Balance as of December 31, 2023	$	44,626		$	136,093		$	8,746		$	2,056		$	191,521
Provision related to current period sales		22,313			162,858			532			5,008			190,711
Provision related to prior period sales		—			(5,589	)		—			107			(5,482	)
Credits/payments made for current period sales		(11,534	)		(105,542	)		—			(3,925	)		(121,001	)
Credits/payments made for prior period sales		(36,485	)		(51,460	)		(577	)		(839	)		(89,361	)
Balance as of March 31, 2024	$	18,920		$	136,360		$	8,701		$	2,407		$	166,388

Such net product revenue allowances and reserves are included within accrued expenses and other current liabilities within the condensed consolidated balance sheets, with the exception of trade allowances and chargebacks, which are included within accounts receivable, net, as discussed above.

Licensing Revenue

The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain rights to VASCEPA for uses that are currently commercialized and under development by the Company. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products. Each of these payments results in licensing and royalty revenues.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

In determining performance obligations, management evaluates whether the license is distinct from the other performance obligations with the collaborative partner based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in the determination include the stage of development of the license delivered, research and development capabilities of the partner and the ability of partners to develop and commercialize VASCEPA independent of the Company.

Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Milestone Payments: At the inception of each arrangement that includes development, regulatory and commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the respective milestone as well as the level of effort and investment required. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of such development, regulatory and commercial milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect licensing revenues and earnings in the period of adjustment.

The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Intangible Asset (Tables)

3 Months Ended

Mar. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Carrying Value of Intangible Asset

The carrying value as of March 31, 2025 and December 31, 2024 is as follows:


In thousands	March 31, 2025			December 31, 2024
Technology rights	$	33,188		$	33,188
Accumulated amortization		(17,528	)		(16,799	)
Intangible asset, net	$	15,660		$	16,389

Leases - Maturity Analysis of Undiscounted Payments for Operating Lease Liabilities and Reconciliation with Carrying Amount of Lease Liability (Detail) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Undiscounted lease payments
Remainder of 2025	$ 2,605
2026	3,289
2027	2,129
2028	1,978
2029	2,011
2030 and thereafter	1,262
Total undiscounted payments	13,274
Discount Adjustments	(2,934)
Current operating lease liability	$ 2,400
Operating lease, liability, current, statement of financial position [Extensible List]	Accrued expenses and other current liabilities
Long-term operating lease liability	$ 7,940	$ 7,723

Intangible Asset - Schedule of Carrying Value of Intangible Asset (Detail) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Technology rights	$ 33,188	$ 33,188
Accumulated amortization	(17,528)	(16,799)
Intangible asset, net	$ 15,660	$ 16,389

Equity - Incentive Equity Awards - Additional Information (Detail) - Employees - Stock Incentive Plan 2020 - shares	1 Months Ended
	Jan. 31, 2025	Feb. 29, 2024
Restricted Stock Units (RSUs)
Stockholders Equity Note [Line Items]
Stock units, Granted	10,646,844	6,800,500
Stock units, Vesting Period		3 years
Stock Options
Stockholders Equity Note [Line Items]
Stock units, Granted		2,662,000
Stock options, Granted	3,313,059
Stock units, Vesting Period		4 years
Stock units, Cliff Vesting Period		1 year

Significant Accounting Policies - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2025 USD ($) Segment Customer	Mar. 31, 2024 USD ($)
Significant Accounting Policies [Line Items]
Trade receivables, credit period	45 days
Maturities period	24 months
Unrealized gain (loss) on held-to-maturity securities	$ 0.1
Segment Reporting, Expense Information Used by CODM, Description	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker, or CODM, in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company currently operates in two business segments, U.S. and Europe, which are aggregated into a single reportable segment, for the development and commercialization of VASCEPA. A single management team that reports to the Company’s CODM, who is the Chief Executive Officer, comprehensively manages the business on an integrated basis for the purpose of allocating resources. The Company’s CODM does not currently assess segment performance or allocate resources based on a measure of total assets nor is it practical for the Company to disaggregate assets based on geography. Accordingly, a total asset measure has not been provided for segment disclosure. Accordingly, the Company does not have separately reportable segments.
Number of reportable segments \| Segment	1
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	srt:ChiefExecutiveOfficerMember
Short Term Investments
Significant Accounting Policies [Line Items]
Maturities period	12 months
Long Term Investments
Significant Accounting Policies [Line Items]
Maturities period	12 months
Money Market Instruments
Significant Accounting Policies [Line Items]
Maturities period	90 days
Gross Product Sales \| Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers \| Customer	3
Customer A \| Gross Product Sales \| Customer Concentration Risk
Significant Accounting Policies [Line Items]
Concentration risk percentage	33.00%	28.00%
Customer A \| Accounts Receivable \| Customer Concentration Risk
Significant Accounting Policies [Line Items]
Concentration risk percentage	36.00%	37.00%
Customer B \| Gross Product Sales \| Customer Concentration Risk
Significant Accounting Policies [Line Items]
Concentration risk percentage	29.00%	35.00%
Customer B \| Accounts Receivable \| Customer Concentration Risk
Significant Accounting Policies [Line Items]
Concentration risk percentage	23.00%	31.00%
Customer C \| Gross Product Sales \| Customer Concentration Risk
Significant Accounting Policies [Line Items]
Concentration risk percentage	29.00%	29.00%
Customer C \| Accounts Receivable \| Customer Concentration Risk
Significant Accounting Policies [Line Items]
Concentration risk percentage	21.00%	22.00%
Internal Revenue Service (IRS)
Significant Accounting Policies [Line Items]
Open tax year	2018 2019
Maximum
Significant Accounting Policies [Line Items]
Unrealized gain (loss) on held-to-maturity securities		$ (0.1)

Intangible Asset

3 Months Ended

Mar. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Asset

(3) Intangible Asset

Intangible asset consists of internal-use software, website development costs and milestone payments to the former shareholders of Laxdale related to the 2004 acquisition of the rights to VASCEPA, which is the result of VASCEPA receiving marketing approval in the U.S. for the MARINE indication in 2012, the REDUCE-IT indication in 2019 and marketing approval in Europe in 2021. In accordance with ASC 350, the Company evaluates the remaining useful life of the intangible asset at each reporting period to determine if any events or circumstances warrant a revision to the remaining period of amortization. As of March 31, 2025, the intangible assets have an estimated weighted-average remaining useful life of 5.9 years. The carrying value as of March 31, 2025 and December 31, 2024 is as follows:


In thousands	March 31, 2025			December 31, 2024
Technology rights	$	33,188		$	33,188
Accumulated amortization		(17,528	)		(16,799	)
Intangible asset, net	$	15,660		$	16,389

Revenue Recognition - Additional Information (Detail)	3 Months Ended
Revenue Recognition - Additional Information (Detail)	Mar. 31, 2025
Disaggregation Of Revenue [Line Items]
Payment period from distributors received from date of sale	45 days
Effect of significant financing component when transfer and customer payment of good or service occurs within one year or less	true
VASCEPA 1-Gram
Disaggregation Of Revenue [Line Items]
Product expiration date after being converted into capsule form	4 years
VASCEPA 0.5-Gram
Disaggregation Of Revenue [Line Items]
Product expiration date after being converted into capsule form	3 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Inventory - Schedule of Inventory (Detail) - USD ($)
$ in Thousands

Mar. 31, 2025

Dec. 31, 2024

Inventory Disclosure [Abstract]

Raw materials

$ 83,236

$ 91,421

Work in process

29,513

30,482

Finished goods

104,145

108,885

Total inventory

^[1]

$ 216,894

$ 230,788

[1]	Total inventory consists of both current inventory and long-term inventory. During the three months ended March 31, 2024, approximately $1.5 million of inventory were expensed through cost of goods sold for product dating inventory.

Significant Accounting Policies - Summary of Reportable Segment Loss Including Significant Reportable Segment Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Product Information [Line Items]
Total revenue, net	$ 42,017	$ 56,519
Less: Cost of goods sold	16,887	24,615
Gross margin	25,130	31,904
Operating expenses:
Selling	7,384	10,250
General and administrative	8,648	9,415
Research and development	2,042	2,217
Payroll and payroll related expense	19,484	18,387
Non-cash stock-based compensation expense	4,327	5,218
Total operating expenses	41,885	45,487
Operating loss	(16,755)	(13,583)
Interest income, net	2,872	3,383
Other income, net	253	1,545
Loss from operations before taxes	(13,630)	(8,655)
Provision for income taxes	(2,067)	(1,298)
Net loss	(15,697)	(9,953)
Product Revenue, Net
Product Information [Line Items]
Total revenue, net	41,035	55,156
Product Revenue, Net \| United States
Product Information [Line Items]
Total revenue, net	35,661	48,114
Product Revenue, Net \| Europe
Product Information [Line Items]
Total revenue, net	5,392	1,865
Product Revenue, Net \| RoW
Product Information [Line Items]
Total revenue, net	(18)	5,177
Licensing and Royalty Revenue
Product Information [Line Items]
Total revenue, net	$ 982	$ 1,363

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2025	Apr. 30, 2025
Document And Entity Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2025
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q1
Trading Symbol	AMRN
Entity Registrant Name	AMARIN CORP PLC\UK
Entity Central Index Key	0000897448
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity File Number	000-21392
Entity Incorporation, State or Country Code	X0
Entity Address, Address Line One	8th Floor
Entity Address, Address Line Two	One Central Plaza
Entity Address, Address Line Three	Dame Street
Entity Address, City or Town	Dublin
Entity Address, Postal Zip Code	D02 K7K5
Entity Address, Country	IE
City Area Code	353 (0) 1
Local Phone Number	6699 020
Document Quarterly Report	true
Document Transition Report	false
Title of each class	American Depositary Shares (ADS(s)), each ADSrepresenting the right to receive twenty (20) Ordinary Shares of Amarin Corporation plc
Name of each exchange on which registered	NASDAQ
Entity Tax Identification Number	00-0000000
American Depositary Shares
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		20,269,174
Ordinary Shares
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		414,140,237

Inventory - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Long-term inventory	$ 57,404	$ 64,740

Nature of Business and Basis of Presentation

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Nature of Business and Basis of Presentation

(1) Nature of Business and Basis of Presentation

Nature of Business

Amarin Corporation plc, or Amarin, or the Company, is a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. The Company is commercialized in the United States, or the U.S., under the brand name VASCEPA® (icosapent ethyl), or VASCEPA. The Company is also commercialized in various European countries, including the United Kingdom, or the UK, and Spain, under the brand name VAZKEPA, hereinafter along with VASCEPA, collectively referred to as VASCEPA. The Company’s operations outside of the U.S. and Europe are in varying stages of development and commercialization with reliance on third-party commercial partners in select geographies, including China, Australia and Canada.

VASCEPA was first approved by the U.S. Food and Drug Administration, or U.S. FDA, in July 2012 for use as an adjunct to diet to reduce triglyceride, or TG, levels in adult patients with severe (>500 mg/dL) hypertriglyceridemia, or the MARINE indication. In January 2013, the Company launched 1-gram size VASCEPA in the U.S. and in October 2016, introduced a 0.5-gram capsule size. On December 13, 2019, the U.S. FDA approved another indication and label expansion for VASCEPA based on the results of the Company’s long-term cardiovascular outcomes trial, REDUCE-IT®, or Reduction of Cardiovascular Events with EPA – Intervention Trial. VASCEPA is approved by the U.S. FDA as an adjunct to maximally tolerated statin therapy for reducing persistent cardiovascular risk in select high risk patients, or the REDUCE-IT indication.

On March 30, 2020, following conclusion of a trial in late January 2020, the U.S. District Court for the District of Nevada, or the Nevada Court, issued a ruling in favor of two generic drug companies, Dr. Reddy’s Laboratories, Inc., or Dr. Reddy’s, and Hikma Pharmaceuticals USA Inc., or Hikma, and certain of their affiliates, or, collectively, the Defendants, that declared as invalid several of the Company's patents covering the MARINE indication. The Company sought appeals of the Nevada Court judgment up to the U.S. Supreme Court, but the Company was unsuccessful. As a result, the following generic versions of icosapent ethyl have obtained U.S. FDA approval with labeling consistent with the MARINE indication of VASCEPA and have entered the U.S. market:


Company	FDA MARINE Indication Approval	1-gram Launch Date	0.5-gram Launch Date
Hikma Pharmaceuticals USA Inc.	May 2020	November 2020	March 2023
Dr. Reddy’s Laboratories, Inc.	August 2020	June 2021	June 2023
Teva Pharmaceuticals USA, Inc.	September 2020	January 2023	September 2022
Apotex, Inc.	June 2021	January 2022	N/A
Zydus Lifesciences	April 2023	–	June 2024
Strides Pharma (1)	September 2023	April 2024	April 2024
Epic Pharma	December 2023	March 2024	N/A
Ascent Pharmaceuticals, Inc. (2)	December 2023	April 2024	April 2024
Qilu Pharmaceutical Co Ltd	November 2024	–	–
Spriaso LLC	December 2024	–	–

(1) Strides Pharma licensed its rights to the generic version of icosapent ethyl to Amneal Pharmaceuticals.

(2) Ascent Pharmaceuticals, Inc. licensed its rights to the generic version of icosapent ethyl to Camber Pharmaceuticals, Inc. and XL Care Pharmaceuticals, Inc.

On March 26, 2021, the European Commission, or EC, approved the marketing authorization application for VAZKEPA, in the European Union, or EU, to reduce the risk of cardiovascular events in high-risk, statin-treated adult patients who have elevated triglycerides (>150 mg/dL) and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk event. On April 22, 2021, the Company announced that the Medicines and Healthcare Products Regulatory Agency, or MHRA, approved VAZKEPA in England, Scotland and Wales to reduce cardiovascular risk. Collectively, CHMP, EMA, EC and MHRA are referred to herein as the European Regulatory Authorities.

On June 1, 2023, the Company announced the National Medical Products Administration, or NMPA, granted approval for VASCEPA under the MARINE indication and the Company's partner, Eddingpharm (Asia) Macao Commercial Offshore Limited, or Edding, launched commercially in October 2023. On June 28, 2024, the Company's partner in China received NMPA approval for VASCEPA in Mainland China for the REDUCE-IT indication. On February 23, 2022, the Hong Kong Department of Health concluded their evaluation and approved the use of VASCEPA under the REDUCE-IT indication.

Amarin is responsible for supplying VASCEPA to all markets in which the branded product is sold, including the U.S., and Europe, as well as in countries where the drug is promoted and sold via collaboration with third-party partners that compensate Amarin for such

supply. Amarin is not responsible for providing any generic company with drug product. The Company operates in one business segment.

Basis of Presentation

The condensed consolidated financial statements included herein have been prepared by the Company in accordance with U.S. Generally Accepted Accounting Principles, or GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, or the Form 10-K, filed with the SEC. The balance sheet amounts in this report were derived from the Company’s audited consolidated financial statements included in the Form 10-K.

The condensed consolidated financial statements reflect all adjustments of a normal and recurring nature that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results for any future period. Certain numbers presented throughout this document may not add precisely to the totals provided due to rounding. Absolute and percentage changes are calculated using the underlying amounts in thousands. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying condensed consolidated financial statements of the Company and subsidiaries have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

Effective as of April 11, 2025, the Company implemented an adjustment to the ratio of its American Depository Shares, or ADSs, to Ordinary Shares from one ADS representing one Ordinary Share to one ADS representing 20 Ordinary Shares, or the ADS Ratio Change. The ADS Ratio Change does not change the Ordinary Shares outstanding. Holders of fractional ADSs resulting from the ADS Ratio Change were to receive a cash payment in lieu of such fractional ADSs. The rate for the cash payment was to be set when the depositary bank aggregated the fractional ADSs and sold them in one or more market trades. All references to ADSs in the accompanying financial statements and notes to the financial statements give retroactive effect to the per-share and share amounts for the ADS Ratio Change for all periods presented herein, unless otherwise specified. In addition, the exercise prices and the numbers of ADSs issuable upon the exercise of any outstanding options or restricted stock units were proportionately adjusted.

At March 31, 2025, the Company had total assets of $655.7 million, of which $281.8 million consisted of cash and short-term investments. More specifically, the Company had current assets of $573.1 million, including cash and cash equivalents of $119.5 million, short-term investments of $162.3 million, accounts receivable, net, of $106.7 million and current inventory of $159.5 million. In addition, as of March 31, 2025, the Company had long-term inventory of $57.4 million. As of March 31, 2025, the Company had no debt outstanding.

Revenue Recognition - Summarize Activity of the Net Product Revenue Allowance and Reserve Categories (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Valuation And Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 113,241	$ 191,521
Provision related to current period sales	186,009	190,711
Provision related to prior period sales	(445)	(5,482)
Credits/payments made for current period sales	(98,200)	(121,001)
Credits/payments made for prior period sales	(105,208)	(89,361)
Ending balance	95,397	166,388
Trade Allowances
Valuation And Qualifying Accounts Disclosure [Line Items]
Beginning balance	9,433	44,626
Provision related to current period sales	16,627	22,313
Credits/payments made for current period sales	(6,461)	(11,534)
Credits/payments made for prior period sales	(9,082)	(36,485)
Ending balance	10,517	18,920
Rebates, Chargebacks and Discounts
Valuation And Qualifying Accounts Disclosure [Line Items]
Beginning balance	97,526	136,093
Provision related to current period sales	164,873	162,858
Provision related to prior period sales	(445)	(5,589)
Credits/payments made for current period sales	(88,769)	(105,542)
Credits/payments made for prior period sales	(93,205)	(51,460)
Ending balance	79,980	136,360
Product Returns
Valuation And Qualifying Accounts Disclosure [Line Items]
Beginning balance	4,734	8,746
Provision related to current period sales	378	532
Credits/payments made for current period sales	(50)
Credits/payments made for prior period sales	(1,276)	(577)
Ending balance	3,786	8,701
Other Incentives
Valuation And Qualifying Accounts Disclosure [Line Items]
Beginning balance	1,548	2,056
Provision related to current period sales	4,131	5,008
Provision related to prior period sales		107
Credits/payments made for current period sales	(2,920)	(3,925)
Credits/payments made for prior period sales	(1,645)	(839)
Ending balance	$ 1,114	$ 2,407

Significant Accounting Policies - Anti-Dilutive Securities Not Included in the Computation of Net Loss per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	30,373	29,492
Restricted Stock and Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	19,716	14,828

Inventory - Schedule of Inventory (Parenthetical) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Inventory Disclosure [Abstract]
Inventory deemed not saleable	$ 1.5

Commitments and Contingencies - Schedule of Antitrust Class Action Lawsuits (Details)	3 Months Ended
	Mar. 31, 2025
Litigation Case One
Loss Contingencies [Line Items]
Lawsuits	Uniformed Fire Officers Association Family Protection Plan Local 854 Uniformed Fire Officers Association for Retired Fire Officers Family Protection Plan
Civil Action #	21-12061
Direct/Indirect Purchasers	Indirect Purchaser
Date Filed	Jun. 02, 2021
Litigation Case Two
Loss Contingencies [Line Items]
Lawsuits	The International Union of Operating Engineers Locals 137, 137A, 137B, 137C, 137R
Civil Action #	21-12416
Direct/Indirect Purchasers	Indirect Purchaser
Date Filed	Jun. 11, 2021
Litigation Case Three
Loss Contingencies [Line Items]
Lawsuits	KPH Healthcare Services, Inc.
Civil Action #	21-12747
Direct/Indirect Purchasers	Direct Purchaser
Date Filed	Jun. 18, 2021
Litigation Case Four
Loss Contingencies [Line Items]
Lawsuits	Local 464A United Food and Commercial Workers Union Welfare Service Benefit Fund
Civil Action #	21-13009
Direct/Indirect Purchasers	Indirect Purchaser
Date Filed	Jun. 25, 2021
Litigation Case Five
Loss Contingencies [Line Items]
Lawsuits	Teamsters Health & Welfare Fund of Philadelphia and Vicinity
Civil Action #	21-13406
Direct/Indirect Purchasers	Indirect Purchaser
Date Filed	Jul. 07, 2021
Litigation Case Six
Loss Contingencies [Line Items]
Lawsuits	Board of Trustees of Heavy and General Laborers’ Local Unions 472 and 172 of N.J. Welfare Fund
Civil Action #	21-14639
Direct/Indirect Purchasers	Indirect Purchaser
Date Filed	Aug. 05, 2021

Significant Accounting Policies - Estimated Fair Value of Assets and Liability (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Asset:
Asset, fair value	$ 249,469	$ 247,178
Money Market Fund
Asset:
Asset, fair value	82,132	67,456
U.S. Treasury Securities
Asset:
Asset, fair value	162,337	174,722
Repo Securities
Asset:
Asset, fair value	5,000	5,000
Level 1
Asset:
Asset, fair value	244,469	242,178
Level 1 \| Money Market Fund
Asset:
Asset, fair value	82,132	67,456
Level 1 \| U.S. Treasury Securities
Asset:
Asset, fair value	162,337	174,722
Level 2
Asset:
Asset, fair value	5,000	5,000
Level 2 \| Repo Securities
Asset:
Asset, fair value	$ 5,000	$ 5,000

Condensed Consolidated Balance Sheets (Parenthetical) - £ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Ordinary Shares, par value per share	£ 0.5	£ 0.5
Ordinary Shares authorized, unlimited	Unlimited	Unlimited
Ordinary Shares, issued	426,842,579	422,256,900
Ordinary Shares, outstanding	414,365,189	411,584,851
Treasury Stock, Shares	12,477,390	10,672,049

Leases - Summary of Components of Lease Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Lessor, Lease, Description [Line Items]
Interest income from sales-type leases	$ 15	$ 16
Operating lease income	$ 249	$ 249
Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)
Lease income	$ 264	$ 265

Inventory

3 Months Ended

Mar. 31, 2025

Inventory Disclosure [Abstract]

Inventory

(4) Inventory

The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA and other global regulatory agencies. Inventories as of March 31, 2025 and December 31, 2024 consist of the following:


In thousands	March 31, 2025		December 31, 2024
Raw materials	$	83,236	$	91,421
Work in process		29,513		30,482
Finished goods		104,145		108,885
Total inventory 1	$	216,894	$	230,788

(1) Total inventory consists of both current inventory and long-term inventory. During the three months ended March 31, 2024, approximately $1.5 million of inventory were expensed through cost of goods sold for product dating inventory.

As of March 31, 2025 and December 31, 2024, the Company had $57.4 million and $64.7 million of long-term inventory, respectively, as consumption is expected beyond the Company's operating cycle of 12 months.

Development, Commercialization and Supply Agreement - Additional Information (Detail) - USD ($)	1 Months Ended						3 Months Ended		12 Months Ended
	Feb. 28, 2025	Oct. 31, 2024	Jan. 31, 2024	Jan. 31, 2020	Sep. 30, 2017	Feb. 28, 2015	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2018	Feb. 28, 2023
License And Collaboration Agreements [Line Items]
Licenses revenue							$ 42,017,000	$ 56,519,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							41,035,000	55,156,000
Mochida Pharmaceutical Co., Ltd. \| In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment	$ 1,000,000		$ 1,000,000
Mochida Pharmaceutical Co., Ltd. \| In-licenses \| Research and Development Expense
License And Collaboration Agreements [Line Items]
Up-front payment										$ 2,700,000
Edding \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received						$ 15,000,000
Sales-based milestone event payment							120,000,000
Edding \| Out-licenses \| Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue							40,081,000		$ 40,081,000
Edding \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							0	3,400,000
Edding \| Out-licenses \| Maximum
License And Collaboration Agreements [Line Items]
Sales-based milestone event payment							50,000,000
Edding \| Out-licenses \| Minimum
License And Collaboration Agreements [Line Items]
Sales-based milestone event payment							5,000,000
Biologix FZCo \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue								0
Biologix FZCo \| Out-licenses \| Maximum \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							100,000
HLS \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received					$ 5,000,000
Non-refundable milestone payment received				$ 3,800,000
HLS \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							0	1,900,000
HLS \| Out-licenses \| Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone					$ 50,000,000
CSL Seqirus \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received		$ 500,000
Non-refundable milestone payment received		1,200,000
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone		1,200,000
Upfront payment receivable											$ 500,000
Event-related milestone payments receivable		6,000,000
Additional product-related milestone payments receivable		$ 4,000,000
CSL Seqirus \| Out-licenses \| Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue							0	0
CSL Seqirus \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							$ 0	$ 0

Leases - Additional Information (Detail) $ in Thousands								3 Months Ended
Leases - Additional Information (Detail) $ in Thousands	Mar. 01, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 01, 2024 USD ($)	Feb. 01, 2023 USD ($)	Oct. 01, 2022	Feb. 01, 2022 USD ($) RenewalOption	Aug. 15, 2019 USD ($) RenewalOption	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)	Jan. 20, 2023 ft²
Lessee Lease Description [Line Items]
Incremental borrowing rate for purposes of calculation of lease liabilities								11.50%
Rent payment								$ 13,274
Operating lease liability								10,300		$ 9,700
Operating lease right-of-use asset								8,363		$ 7,592
Operating lease expense								800	$ 900
Receive rent payment								$ 5,870
Bridgewater
Lessee Lease Description [Line Items]
Lease commencement date							Aug. 15, 2019
Lease agreement term				7 years 6 months			11 years
Number of renewal options \| RenewalOption							2
Lease renewal term							5 years
Description of lease agreement								will have a one-time option to terminate the agreement effective on the first day of the 97th month after the Commencement Date upon advance written notice and a termination payment specified in the Lease.
Lease termination description								one-time option to terminate the agreement effective on the first day of the 97th month after the Commencement Date
Lease termination existence of option to extend							true
Rent payment							$ 100
Lease agreement area \| ft²											67,747
Sublease commencement date				Feb. 01, 2023
Receive rent payment				$ 100
Zug Switzerland
Lessee Lease Description [Line Items]
Lease commencement date						Feb. 01, 2022
Lease agreement term						5 years
Number of renewal options \| RenewalOption						1
Lease renewal term						5 years
Rent payment						$ 200
Dublin
Lessee Lease Description [Line Items]
Lease commencement date	Mar. 01, 2025		Sep. 01, 2024		Oct. 01, 2022
Lease termination date			Feb. 28, 2025
Lease agreement term	2 years		2 years		2 years
Rent payment	$ 900	$ 400	$ 500
Maximum
Lessee Lease Description [Line Items]
Short term lease period								12 months
Maximum \| Vehicles
Lessee Lease Description [Line Items]
Lease agreement term								36 months

Equity (Tables)

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

Summarizes the Aggregate Number of Stock Options And Restricted Stock Unit

The following table summarizes the aggregate number of stock options and RSUs outstanding under the Amarin Corporation plc 2020 Stock Incentive Plan, or the 2020 Plan, as of March 31, 2025:


	March 31, 2025
Outstanding stock options		30,373,266
% of outstanding on a fully-diluted basis		7	%
Outstanding RSUs		19,716,149
% of outstanding on a fully-diluted basis		5	%

Summary of Equity Awards Activity

The following table represents equity awards activity during the three months ended March 31, 2025 and 2024:


	Three months ended March 31,
	2025		2024
Ordinary Shares issued for stock option exercises		—		9,500
Gross and net proceeds from stock option exercises	$	—	$	10,260
Ordinary Shares issued in settlement of vested RSUs		4,328,179		2,651,407
Ordinary Shares retained for settlement of employee tax obligations ─ RSUs		1,687,443		990,070
Ordinary Shares issued in settlement of vested Performance-based RSUs (1)		257,500		468,230
Ordinary Shares retained for settlement of employee tax obligations ─ Performance-based RSUs		117,898		227,380

(1)

Performance-based RSUs vested in connection with the achievement of certain performance conditions during the year.

Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Ordinary Shares	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit
Treasury Stock, Shares			(9,317,202)
Balance at Dec. 31, 2023	$ 552,097	$ 302,756	$ (63,752)	$ 1,899,456	$ (1,586,363)
Balance (in shares) at Dec. 31, 2023		418,141,295
Exercise of stock options	$ 10	$ 6		4
Exercise of stock options (in shares)	9,500	9,500
Vesting of restricted stock units	$ (1,436)	$ 1,980	$ (1,436)	(1,980)
Vesting of restricted stock units (in shares)		3,119,637	(1,217,450)
Stock-based compensation	5,218			5,218
Loss for the period	(9,953)				(9,953)
Balance at Mar. 31, 2024	$ 545,936	$ 304,742	$ (65,188)	1,902,698	(1,596,316)
Balance (in shares) at Mar. 31, 2024		421,270,432
Treasury Stock, Shares			(10,534,652)
Treasury Stock, Shares	10,672,049		(10,672,049)
Balance at Dec. 31, 2024	$ 486,176	$ 305,298	$ (65,326)	1,914,750	(1,668,546)
Balance (in shares) at Dec. 31, 2024		422,256,900
Vesting of restricted stock units	(1,119)	$ 2,854	$ (1,119)	(2,854)
Vesting of restricted stock units (in shares)		4,585,679	(1,805,341)
Stock-based compensation	4,327			4,327
Loss for the period	(15,697)				(15,697)
Balance at Mar. 31, 2025	$ 473,687	$ 308,152	$ (66,445)	$ 1,916,223	$ (1,684,243)
Balance (in shares) at Mar. 31, 2025		426,842,579
Treasury Stock, Shares	12,477,390		(12,477,390)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

Equity - Incentive Equity Awards - Summarizes the Aggregate Number of Stock Options And Restricted Stock Unit (Detail) - Stock Incentive Plan 2020	Mar. 31, 2025 shares
Stock Options
Stockholders Equity Note [Line Items]
Outstanding Stock Options	30,373,266
Restricted Stock Units (RSUs)
Stockholders Equity Note [Line Items]
Outstanding RSUs	19,716,149

Leases (Tables)

3 Months Ended

Mar. 31, 2025

Leases [Abstract]

Maturity Analysis of Undiscounted Payments for Operating Lease Liabilities and Reconciliation with Carrying Amount of Lease Liability

The table below depicts a maturity analysis of the Company’s undiscounted payments for its operating lease liabilities and their reconciliation with the carrying amount of lease liability presented in the statement of financial position as of March 31, 2025:


In thousands	Undiscounted lease payments
Remainder of 2025	$	2,605
2026		3,289
2027		2,129
2028		1,978
2029		2,011
2030 and thereafter		1,262
Total undiscounted payments	$	13,274
Discount Adjustments	$	(2,934	)
Current operating lease liability	$	2,400
Long-term operating lease liability	$	7,940

Summary of Components of Lease Income

The components of lease income are as follows:


	For the Three Months Ended March 31,
In thousands	2025		2024
Interest income from sales-type leases	$	15	$	16
Operating lease income		249		249
Total	$	264	$	265

Leases - Summary of Future Minimum Sales Type Lease and Operating Lease Receivables (Details) $ in Thousands	Mar. 31, 2025 USD ($)
Lessor, Lease, Description [Line Items]
Sales-Type Leases, Remainder of 2025	$ 90
Sales-Type Leases, 2026	122
Sales-Type Leases, 2027	125
Sales-Type Leases, 2028	127
Sales-Type Leases, 2029	130
Sales-Type Leases, 2030 and thereafter	88
Sales-Type Leases, Total	682
Operating Leases. Remainder of 2025	773
Operating Leases, 2026	1,051
Operating Leases, 2027	1,073
Operating Leases, 2028	1,096
Operating Leases, 2029	1,118
Operating Leases, 2030 and thereafter	759
Operating Leases, Total	$ 5,870

Significant Accounting Policies

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Significant Accounting Policies

(2) Significant Accounting Policies

Revenue Recognition

In accordance with Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, or Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For a complete discussion of accounting for net product revenue and licensing revenue, see Note 7—Revenue Recognition.

Cash and Cash Equivalents and Restricted Cash

Cash and cash equivalents consist of cash, deposits with banks and short-term highly liquid money market instruments with original maturities at the date of purchase of 90 days or less. Restricted cash represents cash and cash equivalents pledged to guarantee repayment of certain expenses which may be incurred for business travel under corporate credit cards held by employees.

Accounts Receivable, net

Accounts receivable, net, comprised of trade receivables, are generally due within 45 days and are stated at amounts due from customers. The Company recognizes an allowance for losses on accounts receivable in an amount equal to the estimated probable credit losses net of any recoveries. The allowance is based primarily on assessment of specific identifiable customer accounts considered at risk or uncollectible, as well as an analysis of current receivables aging and expected future write-offs. The expense associated with the allowance for doubtful accounts is recognized as selling, general, and administrative expense. The Company has not historically experienced any significant credit losses. All customer accounts are actively managed and no losses in excess of amounts reserved are currently expected.

The following table summarizes the impact of accounts receivable reserves on the gross trade accounts receivable balances as of March 31, 2025 and December 31, 2024:


In thousands	March 31, 2025			December 31, 2024
Gross trade accounts receivable	$	118,677		$	133,072
Trade allowances		(10,517	)		(9,433	)
Chargebacks		(1,426	)		(1,360	)
Accounts receivable, net	$	106,734		$	122,279

Inventory

The Company states inventory at the lower of cost or net realizable value. Cost is determined based on actual cost using the average cost method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company classifies inventory as long-term inventory when consumption of the inventory is expected beyond the next 12 months. The Company classifies finished goods expected to be sold within the next 12 months, and all of VASCEPA's active pharmaceutical ingredient, or API, as current inventory. An allowance is established when management determines that certain inventories may not be saleable. If inventory cost exceeds expected net realizable value due to obsolescence, damage or quantities in excess of expected demand, changes in price levels or other causes, the Company will reduce the carrying value of such inventory to net realizable value and recognize the difference as a component of cost of goods sold in the period in which it occurs. The Company capitalizes inventory purchases of saleable product from approved suppliers while inventory purchases from suppliers prior to regulatory approval are included as a component of research and development expense. The Company expenses inventory identified for use as marketing samples when they are packaged. The average cost reflects the actual purchase price of VASCEPA API.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other tax attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized. Deferred tax assets and liabilities are classified as non-current in the condensed consolidated balance sheet.

The Company provides reserves for potential payments of tax to various tax authorities and does not recognize tax benefits related to uncertain tax positions and other issues. Tax benefits for uncertain tax positions are based on a determination of whether a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized, assuming that the matter in question will be decided based on its technical merits. The Company’s policy is to record interest and penalties in the provision for income taxes, as applicable.

The Company regularly assesses its ability to realize deferred tax assets. Changes in historical earnings performance, future earnings projections, and changes in tax laws, among other factors, may cause the Company to adjust its valuation allowance on deferred tax assets, which would impact the Company’s income tax expense in the period in which it is determined that these factors have changed.

Excess tax benefits and deficiencies that arise upon vesting or exercise of stock-based payments are recognized as an income tax benefit and expense, respectively, in the condensed consolidated statement of operations. Excess income tax benefits are classified as cash flows from operating activities and cash paid to taxing authorities arising from the withholding of Ordinary Shares from employees are classified as cash flows from financing activities.

The Company’s and its subsidiaries’ income tax returns are periodically examined by various tax authorities, including the Internal Revenue Service, or IRS, and state tax authorities. The Company is currently under audit by the IRS for its 2018 and 2019 U.S.

income tax returns. Although the outcome of tax audits is always uncertain and could result in significant cash tax payments, the Company does not believe the outcome of these audits will have a material adverse effect on its condensed consolidated financial position or results of operations.

Loss per Share

Basic net loss per share is determined by dividing net loss by the weighted average number of Ordinary Shares outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average number of Ordinary Shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive Ordinary Shares, such as from the exercise of stock options and vesting of restricted stock units calculated using the treasury stock method. In periods with reported net operating losses, all stock options and restricted stock units outstanding are deemed anti-dilutive such that basic and diluted net loss per share are equal.


	For the Three Months Ended March 31,
In thousands	2025			2024
Net loss—basic and diluted	$	(15,697	)	$	(9,953	)
Weighted average Ordinary Shares outstanding—basic and diluted		413,422			410,146
Loss per Ordinary Share—basic and diluted	$	(0.04	)	$	(0.02	)

Weighted average ADS outstanding—basic and diluted		20,671			20,507
Loss per ADS—basic and diluted	$	(0.76	)	$	(0.49	)


	For the Three Months Ended March 31,
In thousands of Ordinary Shares	2025		2024
Stock options		30,373		29,492
Restricted stock and restricted stock units		19,716		14,828

Stock options are anti-dilutive during periods of net earnings when the exercise price of the stock options exceeds the market price of the underlying securities on the last day of the reporting period. Restricted stock and restricted stock units are anti-dilutive during periods of net earnings when underlying performance-based vesting requirements were not achieved as of the last day of the reporting period.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents, short-term investments, and accounts receivable. The Company maintains substantially all of its cash and cash equivalents and short-term investments in financial institutions believed to be of high credit quality.

A significant portion of the Company’s sales are to wholesalers in the pharmaceutical industry. The Company monitors the creditworthiness of customers to whom it grants credit terms and has not experienced any credit losses. The Company does not require collateral or any other security to support credit sales. Three customers individually accounted for 10% or more of the Company’s gross product sales. Customers A, B, and C accounted for 33%, 29%, and 29%, respectively, of gross product sales for the three months ended March 31, 2025, and represented 36%, 23%, and 21%, respectively, of the gross accounts receivable balance as of March 31, 2025. Customers A, B, and C accounted for 28%, 35%, and 29%, respectively, of gross product sales for the three months ended March 31, 2024 and represented 37%, 31%, and 22%, respectively, of the gross accounts receivable balance as of March 31, 2024. The Company has not experienced any significant write-offs of its accounts receivable. All customer accounts are actively managed and no losses in excess of amounts reserved are currently expected.

Concentration of Suppliers

The Company has contractual freedom to source the API for VASCEPA and to procure other services supporting its supply chain and has entered into supply agreements with multiple suppliers. The Company’s supply of product for commercial sale and clinical trials is dependent upon relationships with third-party manufacturers and suppliers.

The Company cannot provide assurance that its efforts to procure uninterrupted supply of VASCEPA to meet market demand will continue to be successful or that it will be able to renew current supply agreements on favorable terms or at all. Significant alteration

to or disruption or termination of the Company’s current supply chain or the Company’s failure to enter into new and similar agreements in a timely fashion, if needed, could have a material adverse effect on its business, condition (financial and other), prospects or results of operations.

The Company currently has manufacturing agreements with multiple independent API manufacturers and several independent API encapsulators and packagers for VASCEPA manufacturing. Each of these API manufacturers, encapsulators and packagers is U.S. FDA-approved and certain of these API manufacturers, encapsulators and packagers are also approved by the European Regulatory Authorities for manufacturing VAZKEPA in Europe. These suppliers are also used by the Company to source supply to meet the clinical trial and commercial demands of its partners in other countries. Each of these suppliers has qualified and validated its manufacturing processes. There can be no guarantee that these or other suppliers with which the Company may contract in the future to manufacture VASCEPA or VASCEPA API will remain qualified to do so to its specifications or that these and any future suppliers will have the manufacturing capacity to meet potential global demand for VASCEPA.

Fair Value of Financial Instruments

The Company provides disclosure of financial assets and financial liabilities that are carried at fair value based on the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements may be classified based on the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities using the following three levels:

Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2—Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3—Unobservable inputs that reflect the Company’s estimates of the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.


	March 31, 2025
In thousands	Total		Level 1		Level 2		Level 3
Asset:
U.S. Treasury Securities	$	162,337	$	162,337	$	—	$	—
Money Market Fund		82,132		82,132		—		—
Repo Securities		5,000		—		5,000		—
Total	$	249,469	$	244,469	$	5,000	$	-


	December 31, 2024
In thousands	Total		Level 1		Level 2		Level 3
Asset:
U.S. Treasury Securities	$	174,722	$	174,722	$	—	$	—
Money Market Fund		67,456		67,456		—		—
Repo Securities		5,000		—		5,000		—
Total	$	247,178	$	242,178	$	5,000	$	—

The carrying amount of the Company’s cash and cash equivalents approximates fair value because of their short-term nature. The cash and cash equivalents consist of cash, deposits with banks and short-term highly liquid money market instruments with remaining maturities at the date of purchase of 90 days or less.

The Company’s investments are stated at amortized cost, which approximates fair value. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 24 months. Those with original maturities greater than 90 days and maturities less than 12 months are included in short-term investments on its condensed consolidated balance sheet. Those with remaining maturities in excess of 12 months are included in long-term investments on its condensed consolidated balance sheet.

Unrealized gains or losses are not recognized until maturity, except other-than-temporary unrealized losses, which are recognized in earnings in the period incurred. The Company evaluates securities with unrealized losses to determine whether such losses are other than temporary. The unrealized gain or loss for the three months ended March 31, 2025 and 2024 was a gain of $0.1 million and a loss

of less than $0.1 million, respectively. Interest on investments is reported in interest income in our condensed consolidated statement of operations. Interest receivable in investment securities is reported in prepaid and other current assets in our condensed consolidated balance sheet.

The carrying amounts of accounts payable and accrued liabilities approximate fair value because of their short-term nature.

Segment and Geographical Information

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker, or CODM, in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company currently operates in two business segments, U.S. and Europe, which are aggregated into a single reportable segment, for the development and commercialization of VASCEPA. A single management team that reports to the Company’s CODM, who is the Chief Executive Officer, comprehensively manages the business on an integrated basis for the purpose of allocating resources. The Company’s CODM does not currently assess segment performance or allocate resources based on a measure of total assets nor is it practical for the Company to disaggregate assets based on geography. Accordingly, a total asset measure has not been provided for segment disclosure. Accordingly, the Company does not have separately reportable segments.

The table below is a summary of the reportable segment loss, including significant reportable segment expenses:


	For the Three Months Ended March 31,
In thousands	2025			2024
US product revenue, net	$	35,661		$	48,114
Europe product revenue, net		5,392			1,865
RoW product revenue, net		(18	)		5,177
Total product revenue, net		41,035			55,156
Licensing and royalty revenue		982			1,363
Total revenue, net		42,017			56,519
Less: Cost of goods sold		16,887			24,615
Gross margin		25,130			31,904
Operating expenses:
Selling		7,384			10,250
General and administrative		8,648			9,415
Research and development		2,042			2,217
Payroll and payroll related expense		19,484			18,387
Non-cash stock-based compensation expense		4,327			5,218
Total operating expenses		41,885			45,487
Operating loss		(16,755	)		(13,583	)
Interest income, net		2,872			3,383
Other income, net		253			1,545
Loss from operations before taxes		(13,630	)		(8,655	)
Provision for income taxes		(2,067	)		(1,298	)
Segment & consolidated net loss	$	(15,697	)	$	(9,953	)

Restructuring

The Company identifies a restructuring event as a program that is planned and controlled by management, and materially changes either the scope of the Company's business or the manner in which that business is conducted. The accounting for involuntary termination benefits that are provided pursuant to a one-time benefit arrangement are accounted for under ASC 420 – Exit or Disposal Cost Obligations, whereas involuntary termination benefits that are part of an ongoing written or substantive plan are accounted for under ASC 712 – Compensation – Nonretirement Postemployment Benefits. The Company accrues a liability for termination benefits under ASC 712 when it is probable that a liability has been incurred and the amount can be reasonably estimated and under ASC 420 when the termination benefits are communicated.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, and are adopted early by the Company or adopted as of the specified effective date.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures, which provides more transparency about income tax information through improvements to income tax disclosures primarily related to the

rate reconciliation and income taxes paid information. This change is effective for annual periods beginning after December 15, 2024. The Company expects adoption of this ASU will result in additional disclosures in line with the requirements of ASU 2023-09.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires a public business entity to disclose specific information about certain costs and expenses in the notes to its financial statements for interim and annual reporting periods beginning after December 15, 2026. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on the Company’s consolidated financial statements.

The Company believes that the impact of other recently issued but not yet adopted accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to the Company’s operations.

Significant Accounting Policies - Summary of Impact of Accounts Receivable Reserves on Gross Trade Accounts Receivable Balances (Detail) - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross trade accounts receivable	$ 118,677	$ 133,072
Accounts receivable, net	106,734	122,279
Trade Allowances
Accounts, Notes, Loans and Financing Receivable [Line Items]
Valuation allowances and reserves	(10,517)	(9,433)
Chargebacks
Accounts, Notes, Loans and Financing Receivable [Line Items]
Valuation allowances and reserves	$ (1,426)	$ (1,360)

Nature of Business and Basis of Presentation - Additional Information (Detail)			3 Months Ended
	Apr. 11, 2025	Mar. 12, 2025	Mar. 31, 2025 USD ($) Segment	Dec. 31, 2024 USD ($)
Product Information [Line Items]
Number of operating segments \| Segment			1
Total assets			$ 655,677,000	$ 685,349,000
Cash and short-term investments			281,800,000
Total current assets			573,061,000	595,399,000
Cash and cash equivalents			119,524,000	121,038,000
Short-term investments			162,263,000	173,182,000
Accounts receivable, net			106,734,000	122,279,000
Current inventory			159,490,000	166,048,000
Long-term inventory			57,404,000	$ 64,740,000
Debt outstanding			$ 0
Ordinary Shares
Product Information [Line Items]
Effective date of ratio change		Apr. 11, 2025
Ratio change on American Depositary Shares, or ADS		20
Ordinary Shares \| Subsequent Event
Product Information [Line Items]
Effective date of ratio change	Apr. 11, 2025
Ratio change on American Depositary Shares, or ADS	20

Commitments and Contingencies

3 Months Ended

Mar. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

(5) Commitments and Contingencies

Amarin accrues a liability for legal contingencies when it believes that it is both probable that a liability has been incurred and that it can reasonably estimate the amount of the loss. Amarin reviews these accruals and adjusts them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and Amarin’s views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in Amarin’s accrued liabilities would be recorded in the period in which such determination is made. For the matters referenced below, the amount of liability is not probable nor can the amount be reasonably estimated; therefore, accruals have not been made. In addition, in accordance with the relevant authoritative guidance, for matters in which the likelihood of material loss is at least reasonably possible, Amarin provides disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, Amarin will provide disclosure to that effect.

Litigation Updates

Amarin intends to vigorously enforce its intellectual property rights relating to VASCEPA, but cannot predict the outcome of these lawsuits described below, those lawsuits described in the Company's Form 10-K or any subsequently filed lawsuits. Except as described below, there have been no material updates to our litigation as reported in the Company’s Form 10-K.

On April 27, 2021 and February 21, 2023, Dr. Reddy’s and Hikma, respectively, filed complaints against the Company in the U.S. District Court for the District of New Jersey, Civil action No. 21-cv-10309 and No. 23-cv-01016, alleging various antitrust violations stemming from alleged anticompetitive practices related to the supply of active pharmaceutical ingredient of VASCEPA. DRL's complaint also includes a state law tortious interference claim related to the same alleged conduct. On March 28, 2024, Teva Pharmaceuticals USA, Inc., or Teva, filed a complaint against the Company in the U.S. District Court for the District of New Jersey, Civil action No. 24-cv-04341 alleging various antitrust violations analogous to those made by Dr. Reddy’s and Hikma. Further, on June 14, 2024, Apotex, Inc., or Apotex, filed a complaint against the Company in the U.S. District Court for the District of New Jersey. Civil action No. 24-cv-07041 alleging various antitrust violations analogous to those made by Dr. Reddy’s, Hikma and Teva, as well as a breach of contract claim related to the same alleged conduct. Apotex also seeks declaratory judgement regarding the applicability of a 2020 settlement agreement to its antitrust claims. In October 2024, Apotex amended its complaint to add as defendants KD Pharma-Bexbach GmbH; KD Swiss GmbH; Marine Ingredients, LLC; Innova Softgel, LLC; 03 Holding GmbH; Capiton AG. Relief sought include an unspecified amount of damages for alleged economic harm to each of Dr. Reddy’s, Hikma, Teva and Apotex, treble damages, other costs and fees and injunctive relief against the alleged violative activities. Amarin believes it has valid defenses and will vigorously defend against the claims. Such litigation can be lengthy, costly and could materially affect and disrupt our business.

Amarin is named as a defendant in six antitrust class action lawsuits in the District Court for the District of New Jersey, as displayed in the table below. Each of the six antitrust class action lawsuits allege Amarin and its co-defendant suppliers violated federal antitrust laws by monopolizing and engaging in a conspiracy to restrain trade in the icosapent ethyl drug and API markets. The Indirect Purchaser Plaintiffs also assert related state antitrust, consumer protection, and unjust enrichment claims. The Indirect Purchaser Plaintiffs seek relief in the form of an unspecified amount of compensatory damages, treble damages, other costs and fees, restitution, and declaratory and injunctive relief against the alleged violative activities. The Direct Purchaser plaintiffs seek treble damages and other costs and fees.


Lawsuits	Civil Action #	Direct/Indirect Purchasers	Date Filed
Uniformed Fire Officers Association Family Protection Plan Local 854 Uniformed Fire Officers Association for Retired Fire Officers Family Protection Plan	21-12061	Indirect Purchaser	6/2/2021
The International Union of Operating Engineers Locals 137, 137A, 137B, 137C, 137R	21-12416	Indirect Purchaser	6/11/2021
KPH Healthcare Services, Inc.	21-12747	Direct Purchaser	6/18/2021
Local 464A United Food and Commercial Workers Union Welfare Service Benefit Fund	21-13009	Indirect Purchaser	6/25/2021
Teamsters Health & Welfare Fund of Philadelphia and Vicinity	21-13406	Indirect Purchaser	7/7/2021
Board of Trustees of Heavy and General Laborers’ Local Unions 472 and 172 of N.J. Welfare Fund	21-14639	Indirect Purchaser	8/5/2021

Such antitrust litigation and antitrust investigations, can be lengthy, costly and could materially affect and disrupt the Company’s business. The Company believes it has valid defenses and will vigorously defend against the claims, but cannot predict when these matters will be resolved, their outcome or their potential loss exposure or impact on the Company’s business. If it is determined that Amarin has violated antitrust law, the Company could be subject to significant civil fines and penalties.

In June 2020, the Company received a civil investigative demand, or CID, from the U.S. Department of Justice, or the DOJ, informing Amarin that the DOJ is investigating whether aspects of its promotional speaker programs and copayment waiver program during the period going back to January 1, 2015, violated the U.S. Anti-Kickback Statute and the U.S. Civil False Claims Act, in relation to the sale and marketing of VASCEPA by the Company and its previous co-marketing partner, Kowa Pharmaceuticals America, Inc. The inquiries require the Company to produce documents and answer written questions, or interrogatories, relevant to specified time periods. Amarin is cooperating with the government agencies and cannot predict when these investigations will be resolved, the outcome of the investigations or their potential impact on the Company's business.

On October 21, 2021, a purported investor in the Company’s publicly traded securities filed a putative class action lawsuit against the Company, the former chief executive officer and the former chief financial officer in the U.S. District Court for the District of New Jersey, Vincent Dang v. Amarin Corporation plc, John F. Thero and Michael W. Kalb, No. 1:21-cv-19212 (D.N.J. Oct. 21, 2021). A subsequent case, Dorfman v. Amarin Corporation plc, et al., No. 3:21-cv-19911 (D.N.J. filed Nov. 10, 2021), was filed in November 2021. In December 2021, several Amarin shareholders moved to consolidate the cases and appoint a lead plaintiff and lead counsel pursuant to the Private Securities Litigation Reform Act. The complaints in these actions are nearly identical and allege that the Company misled investors by allegedly downplaying the risk associated with the Company’s patent litigation related to its Abbreviated New Drug Application, or ANDA, that sought U.S. FDA approval for the sale of generic versions of icosapent ethyl, or

ANDA litigation, and the risk that certain of the Company’s patents related to the MARINE indication would be invalidated. Based on these allegations, plaintiffs allege that they purchased securities at an inflated share price and brought claims under the Securities and Exchange Act of 1934 seeking unspecified monetary damages and attorneys’ fees and costs. In October 2022, the court consolidated the cases and appointed a lead plaintiff for the putative class. On January 13, 2023, lead plaintiff filed an amended complaint that also named the former general counsel, and again alleged that the Company made false statements regarding the ANDA litigation as well as about the REDUCE-IT indication and VASCEPA’s financial prospects resulting from REDUCE-IT. All defendants have moved to dismiss the amended complaint and on September 25, 2024, the New Jersey District Court granted the Company’s motion to dismiss for all counts, without prejudice, permitting the Plaintiffs 30 days to amend and refile their lawsuit. On October 24, 2024, the court subsequently granted the Plaintiffs request for an additional 30 days to amend and refile the complaint. On November 6, 2024, the Plaintiffs advised the court that they would not refile their complaint, closing the case.

On March 29, 2023, purported investors in the Company’s publicly traded securities filed a derivative lawsuit, naming as defendants the Company’s former general counsel, the Company’s trial counsel for the ANDA litigation, and the Company as nominal defendant, in the Superior Court of New Jersey, Law Division, Monmouth County, captioned Anne Abramson, John Lissandrello, Georgette Appiano, and Andrew Bondarowicz v. Amarin Corporation plc, Covington & Burling, LLP, Joseph T. Kennedy, and John Does A-Z, No. MON-L-000984-23 (N.J. Super. Ct. Law Div. Mar. 29, 2023). The complaint alleged that the defendants failed to exercise appropriate diligence and due care in their conduct of the ANDA litigation. Based on those allegations, the complaint alleged that the defendants committed legal malpractice and sought monetary damages and attorneys’ fees and costs. On April 8, 2023, the plaintiffs voluntarily dismissed this case without prejudice.

On November 30, 2020, the Company filed a patent infringement lawsuit against Hikma for making, selling, offering to sell, and importing generic icosapent ethyl capsules in and into the U.S. in a manner that the Company alleges induced the infringement of patents covering the use of VASCEPA to reduce specified CV risk. On January 4, 2022, the district court for the District of Delaware granted a motion to dismiss the Company's lawsuit for failure to state a claim. Thereafter, the Company appealed to the Court of Appeals for the Federal Circuit. On June 25, 2024, the Federal Circuit issued a decision reversing the district court, finding that the Company's allegations against Hikma plausibly state a claim alleging Hikma actively induced infringement of the asserted patents. Hikma filed a petition for rehearing en banc on August 22, 2024, which was denied on October 17, 2024. On February 14, 2025, Hikma filed a Petition for a Writ of Certiorari with the Supreme Court of the United States seeking review of the Federal Circuit decision reversing the district court. The infringement case continues to proceed within the district court during the pendency of the Petition.

On March 31, 2023, the Company’s former chief executive officer, Karim Mikhail, filed a complaint against the Company and certain of its affiliates in the Superior Court of New Jersey, Law Division – Somerset County, captioned Mikhail v. Amarin Corporation, plc (Docket No. SOM-L-000366-23), concerning Mr. Mikhail’s alleged “constructive termination” from the Company. The complaint seeks unspecified damages arising from claims for breaches of his employment agreement, Executive Severance and Change of Control Plan, and the implied covenant of good faith and fair dealing. On April 3, 2023, the case moved to the U.S. District Court for the District of New Jersey (Civ. No. 3:23-cv-01856). On June 30, 2023, all defendants moved to dismiss this case without prejudice due to lack of jurisdiction. On March 4, 2024, the District Court granted the motion in part and denied the motion in part, permitting the parties to pursue limited discovery on the issue of personal jurisdiction. On March 20, 2025, the Company filed a new Motion to Dismiss for failure of plaintiff to state a claim. The Company believes it has valid defenses and will vigorously defend against the claims but cannot predict the outcome. The Company is unable to reasonably estimate the loss exposure, if any, associated with these claims.

In addition to the above, in the ordinary course of business, the Company is from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements and other matters.

Milestone and Supply Purchase Obligations

The Company currently has long-term supply agreements with multiple API suppliers and encapsulators. The Company is relying on these suppliers to meet current and potential future global demand for VASCEPA. Certain supply agreements require annual minimum volume commitments by the Company and certain volume shortfalls may require payments for such shortfalls.

These agreements include requirements for the suppliers to meet certain product specifications and qualify their materials and facilities with applicable regulatory authorities, including the U.S. FDA. The Company has incurred certain costs associated with the qualification of product produced by these suppliers.

The Company continues to negotiate with contract suppliers to align its supply arrangements with current and future global demand, which may result in additional costs to the Company. As of the date of filing of this Quarterly Report, the Company has a total of approximately $61.2 million in future contractual purchase obligations without consideration to ongoing discussions with other suppliers. In addition, the Company has total obligations of $152.8 million contingent on either certain suppliers obtaining regulatory approval in Europe or obtaining pricing reimbursement in certain European countries.

Also, under the Laxdale agreement, upon receipt of a marketing approval in Europe for a further indication of VASCEPA (or further indication of any other product acquired from Laxdale in 2004), the Company must make an aggregate stock or cash payment (at the

sole option of each such former shareholder) of £5.0 million (approximately $6.5 million as of March 31, 2025) for the potential market approval.

The Company has no provision for any of these obligations since the amounts are either not paid or payable as of March 31, 2025.

Equity - ADS - Additional Information (Detail) - Ordinary Shares	Mar. 12, 2025
Stockholders Equity Note [Line Items]
Ratio change on American Depositary Shares, or ADS	20
Effective date of ratio change	Apr. 11, 2025

Development, Commercialization and Supply Agreement - Recognized Revenues Changes in Contract Asset and Contract Liability Balances (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenue recognized in the period from:
Amounts included in contract liability at the beginning of the period	$ 0	$ 401

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (15,697)	$ (9,953)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization	1	33
Accretion of investments	(1,216)	(1,547)
Stock-based compensation	4,327	5,218
Amortization of intangible asset	729	729
Changes in assets and liabilities:
Accounts receivable, net	15,545	17,757
Inventory	13,894	6,726
Prepaid and other current assets	(12,577)	3,476
Other long-term assets	39	36
Interest receivable	450
Deferred revenue		(401)
Accounts payable and other current liabilities	(17,541)	(34,896)
Other long-term liabilities	(413)	221
Net cash used in operating activities	(12,459)	(12,601)
CASH FLOWS FROM INVESTING ACTIVITIES:
Maturities of securities	55,000	62,000
Purchases of securities	(42,936)	(33,281)
Net cash provided by investing activities	12,064	28,719
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options		10
Taxes paid related to stock-based awards	(1,119)	(1,436)
Net cash used in financing activities	(1,119)	(1,426)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(1,514)	14,692
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	121,338	199,777
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	119,824	214,469
Cash paid during the year for:
Income taxes	22	29
Supplemental disclosure of non-cash transactions:
Initial recognition of operating lease right-of-use asset	$ 1,837	$ 81

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Revenue Recognition

Cash and Cash Equivalents and Restricted Cash

Accounts Receivable, net

The following table summarizes the impact of accounts receivable reserves on the gross trade accounts receivable balances as of March 31, 2025 and December 31, 2024:


In thousands	March 31, 2025			December 31, 2024
Gross trade accounts receivable	$	118,677		$	133,072
Trade allowances		(10,517	)		(9,433	)
Chargebacks		(1,426	)		(1,360	)
Accounts receivable, net	$	106,734		$	122,279

Inventory

Income Taxes

Loss per Share


	For the Three Months Ended March 31,
In thousands	2025			2024
Net loss—basic and diluted	$	(15,697	)	$	(9,953	)
Weighted average Ordinary Shares outstanding—basic and diluted		413,422			410,146
Loss per Ordinary Share—basic and diluted	$	(0.04	)	$	(0.02	)

Weighted average ADS outstanding—basic and diluted		20,671			20,507
Loss per ADS—basic and diluted	$	(0.76	)	$	(0.49	)


	For the Three Months Ended March 31,
In thousands of Ordinary Shares	2025		2024
Stock options		30,373		29,492
Restricted stock and restricted stock units		19,716		14,828

Concentration of Credit Risk

Fair Value of Financial Instruments

Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.


	March 31, 2025
In thousands	Total		Level 1		Level 2		Level 3
Asset:
U.S. Treasury Securities	$	162,337	$	162,337	$	—	$	—
Money Market Fund		82,132		82,132		—		—
Repo Securities		5,000		—		5,000		—
Total	$	249,469	$	244,469	$	5,000	$	-


	December 31, 2024
In thousands	Total		Level 1		Level 2		Level 3
Asset:
U.S. Treasury Securities	$	174,722	$	174,722	$	—	$	—
Money Market Fund		67,456		67,456		—		—
Repo Securities		5,000		—		5,000		—
Total	$	247,178	$	242,178	$	5,000	$	—

The carrying amounts of accounts payable and accrued liabilities approximate fair value because of their short-term nature.

Segment and Geographical Information

The table below is a summary of the reportable segment loss, including significant reportable segment expenses:


	For the Three Months Ended March 31,
In thousands	2025			2024
US product revenue, net	$	35,661		$	48,114
Europe product revenue, net		5,392			1,865
RoW product revenue, net		(18	)		5,177
Total product revenue, net		41,035			55,156
Licensing and royalty revenue		982			1,363
Total revenue, net		42,017			56,519
Less: Cost of goods sold		16,887			24,615
Gross margin		25,130			31,904
Operating expenses:
Selling		7,384			10,250
General and administrative		8,648			9,415
Research and development		2,042			2,217
Payroll and payroll related expense		19,484			18,387
Non-cash stock-based compensation expense		4,327			5,218
Total operating expenses		41,885			45,487
Operating loss		(16,755	)		(13,583	)
Interest income, net		2,872			3,383
Other income, net		253			1,545
Loss from operations before taxes		(13,630	)		(8,655	)
Provision for income taxes		(2,067	)		(1,298	)
Segment & consolidated net loss	$	(15,697	)	$	(9,953	)

Restructuring

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, and are adopted early by the Company or adopted as of the specified effective date.

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current Assets:
Cash and cash equivalents	$ 119,524	$ 121,038
Restricted cash	300	300
Short-term investments	162,263	173,182
Accounts receivable, net	106,734	122,279
Inventory	159,490	166,048
Prepaid and other current assets	24,750	12,552
Total current assets	573,061	595,399
Property, plant and equipment, net	15	16
Long-term inventory	57,404	64,740
Operating lease right-of-use asset	8,363	7,592
Other long-term assets	1,174	1,213
Intangible asset, net	15,660	16,389
TOTAL ASSETS	655,677	685,349
Current Liabilities:
Accounts payable	45,661	40,366
Accrued expenses and other current liabilities	116,747	139,583
Total current liabilities	162,408	179,949
Long-Term Liabilities:
Long-term operating lease liability	7,940	7,723
Other long-term liabilities	11,642	11,501
Total liabilities	181,990	199,173
Commitments and contingencies (Note 5)
Stockholders’ Equity:
Ordinary Shares, GBP 0.50 par value per share, unlimited authorized; 426,842,639 shares issued, 41,365,249 shares outstanding as of March 31, 2025; 422,256,960 shares issued, 411,584,911 shares outstanding as of December 31, 2024	308,152	305,298
Additional paid-in capital	1,916,223	1,914,750
Treasury stock; 12,477,390 shares as of March 31, 2025; 10,672,049 shares as of December 31, 2024	(66,445)	(65,326)
Accumulated deficit	(1,684,243)	(1,668,546)
Total stockholders’ equity	473,687	486,176
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 655,677	$ 685,349

Intangible Asset - Additional Information (Detail)	Mar. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets estimated weighted-average remaining useful life	5 years 10 months 24 days

Development, Commercialization and Supply Agreements - Summary of Licensing Revenue (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Mar. 31, 2025

Mar. 31, 2024

Dec. 31, 2024

License And Collaboration Agreements [Line Items]

Revenue recognized related to upfront and milestone payments

$ 401

Revenue recognized related to upfront and milestone payments

$ 0

Licenses revenue

42,017

56,519

Edding | Out-licenses

License And Collaboration Agreements [Line Items]

Revenue recognized related to upfront and milestone payments

^[1]

Revenue recognized related to upfront and milestone payments

^[1]

$ 376

Edding | Out-licenses | Licensing Revenue

License And Collaboration Agreements [Line Items]

Licenses revenue

$ 40,081

[1]

Licensing revenue under the DCS Agreement is recognized concurrent with the input measure of support hours provided by Amarin to Edding in achieving the combined development and regulatory performance obligation, which in the Company’s judgment is the best measure of progress towards satisfying this performance obligation.

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2025	Mar. 31, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ (15,697)	$ (9,953)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Development, Commercialization and Supply Agreement - Changes in Balances of Contract Assets and Liabilities (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Contract liabilities:
Deferred revenue, Balance at Beginning of Period	$ 0	$ 4,850
Deferred revenue, Additions	0	0
Deferred revenue, Deductions		(401)
Deferred revenue, Deductions	0
Deferred revenue, Balance at End of Period	$ 0	$ 4,449

Commitments and Contingencies - Additional Information (Detail) - Mar. 31, 2025 $ in Millions	GBP (£)	USD ($)
Commitments And Contingencies Disclosure [Line Items]
Future contractual purchase obligation without consideration		$ 61.2
Regulatory Approval in Europe
Commitments And Contingencies Disclosure [Line Items]
Additional future contractual purchase obligations without consideration		152.8
Further Indication for AMR101 \| Potential Marketing Approval 1
Commitments And Contingencies Disclosure [Line Items]
Aggregate stock or cash payment upon potential market approval	£ 5,000,000	6.5
Further Indication for AMR101 \| Potential Marketing Approval 2
Commitments And Contingencies Disclosure [Line Items]
Aggregate stock or cash payment upon potential market approval	£ 5,000,000	$ 6.5

Significant Accounting Policies - Calculation of Net Loss and Number of Ordinary Shares Used to Compute Basic and Diluted Net Loss per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Significant Accounting Policies [Line Items]
Net loss - basic	$ (15,697)	$ (9,953)
Net loss - diluted	$ (15,697)	$ (9,953)
Weighted average shares outstanding - basic	413,422	410,146
Weighted average shares outstanding - diluted	413,422	410,146
Loss per share - basic	$ (0.04)	$ (0.02)
Loss per share - diluted	$ (0.04)	$ (0.02)
American Depositary Shares
Significant Accounting Policies [Line Items]
Weighted average shares outstanding - basic	20,671	20,507
Weighted average shares outstanding - diluted	20,671	20,507
Loss per share - basic	$ (0.76)	$ (0.49)
Loss per share - diluted	$ (0.76)	$ (0.49)
Ordinary Shares
Significant Accounting Policies [Line Items]
Weighted average shares outstanding - basic	413,422	410,146
Weighted average shares outstanding - diluted	413,422	410,146
Loss per share - basic	$ (0.04)	$ (0.02)
Loss per share - diluted	$ (0.04)	$ (0.02)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.

+ References + Details

Leases

3 Months Ended

Mar. 31, 2025

Leases [Abstract]

Leases

(9) Leases

Lessee

The Company leases office space under operating leases. The lease liability is initially measured at the present value of the lease payments to be made over the lease term. Lease payments are comprised of the fixed and variable payments to be made by the Company to the lessor during the lease term minus any incentives or rebates or abatements receivable by the Company from the lessor or the owner. Payments for non-lease components do not form part of lease payments. The lease term includes renewal options only if these options are specified in the lease agreement and if failure to exercise the renewal option imposes a significant economic penalty for the Company. As there are no significant economic penalties, renewal cannot be reasonably assured and the lease terms for the office space do not include any renewal options. The Company has not entered into any leases with related parties. The Company accounts for short-term leases (i.e., lease term of 12 months or less) by making the short-term lease policy election and will not apply the recognition and measurement requirements of ASC 842.

The Company has determined that the rate implicit in the lease is not determinable and the Company does not have borrowings with similar terms and collateral. Therefore, the Company considered a variety of factors, including the Company’s credit rating, observable debt yields from comparable companies with a similar credit profile and the volatility in the debt market for securities with similar terms, in determining that 11.5% was reasonable to use as the incremental borrowing rate for purposes of the calculation of lease liabilities and a change of 1% would not result in a material change to the Company’s condensed consolidated financial statements.

On February 5, 2019, the Company entered into a lease agreement for new office space in Bridgewater, New Jersey, or the Lease. The Lease commenced on August 15, 2019, or the Commencement Date, for an 11-year period, with two five-year renewal options. Subject to the terms of the Lease, Amarin will have a one-time option to terminate the agreement effective on the first day of the 97th month after the Commencement Date upon advance written notice and a termination payment specified in the Lease. Under the Lease, the Company paid monthly rent of approximately $0.1 million for the first year following the Commencement Date, and such rent

increases by a nominal percentage every year following the first anniversary of the Commencement Date. In addition, Amarin receives certain abatements subject to the limitations in the Lease.

On November 17, 2021, the Company entered into a lease agreement for office space in Zug Switzerland, or the Zug Lease. The Zug Lease commenced on February 1, 2022, or the Zug Commencement Date, for a five-year period, with one five-year renewal option. Under the Zug Lease, the Company will pay annual rent of approximately $0.2 million for the first year following the Zug Commencement Date, and such rent increases by a nominal percentage every year following the first anniversary of the Zug Commencement Date.

On September 13, 2022, the Company entered into a lease agreement for office space in Dublin, Ireland, or the Dublin Lease. The Dublin Lease commenced on October 1, 2022, or the Dublin Commencement Date, for a two-year period. Under the Dublin Lease, the Company paid annual rent of approximately $0.4 million during the duration of the lease term, which ended on September 30, 2024.

On April 26, 2024, the Company entered into a lease agreement for new office space in Dublin, Ireland, or the Subsequent Dublin Lease. The Subsequent Dublin Lease commenced on September 1, 2024, or the Subsequent Dublin Commencement Date, for a two-year period. Under the Subsequent Dublin Lease, the Company paid annual rent of approximately $0.5 million during the duration of the lease term, which was terminated effective on February 28, 2025.

On February 11, 2025, the Company entered into an amended lease agreement, which amended the Subsequent Dublin Lease, for additional office space in Dublin, Ireland, or the Amended Subsequent Dublin Lease. The Amended Subsequent Dublin Lease commenced on March 1, 2025, or the Amended Subsequent Dublin Commencement Date, for a two-year period. Under the Amended Subsequent Dublin Lease, the Company will pay annual rent of approximately $0.9 million during the duration of the lease term.

In addition to the real estate leases, the Company continually enters into lease agreements for various vehicles with terms ranging from month-to-month up to 36 months.

The total operating lease liability is $10.3 million and $9.7 million and the total operating lease right-of-use asset is $8.4 million and $7.6 million, as of March 31, 2025 and December 31, 2024, respectively.

The lease expense for the three months ended March 31, 2025 and 2024 is approximately $0.8 million and $0.9 million, respectively.


In thousands	Undiscounted lease payments
Remainder of 2025	$	2,605
2026		3,289
2027		2,129
2028		1,978
2029		2,011
2030 and thereafter		1,262
Total undiscounted payments	$	13,274
Discount Adjustments	$	(2,934	)
Current operating lease liability	$	2,400
Long-term operating lease liability	$	7,940

Lessor

The Company classifies contractual lease arrangements entered as a lessor as a sales-type, direct financing or operating lease as described in ASC 842. For sales-type leases, the Company derecognizes the leased asset and recognizes the lease investment on the balance sheet.

On January 20, 2023, the Company entered into a sublease agreement, or the Sublease, for 50,000-square feet of the 67,747-square foot Lease and included within the sublease are furniture, fixtures and equipment, collectively the Sublease. The Sublease commenced on February 1, 2023, or the Sublease Commencement Date, for a 7.5-year period. Under the Sublease, the Company will be paid monthly rent of approximately $0.1 million for the first year following the Sublease Commencement Date, and such rent increases by a nominal percentage every year following the first anniversary of the Sublease Commencement Date. In addition, the Company will provide certain abatements subject to the limitations in the Lease.

The components of lease income are as follows:


	For the Three Months Ended March 31,
In thousands	2025		2024
Interest income from sales-type leases	$	15	$	16
Operating lease income		249		249
Total	$	264	$	265

Future minimum sales-type lease and operating lease receivables as of March 31, 2025 are as follows:


In thousands	Sales-Type Leases		Operating Leases
Remainder of 2025	$	90	$	773
2026		122		1,051
2027		125		1,073
2028		127		1,096
2029		130		1,118
2030 and thereafter		88		759
Total	$	682	$	5,870

Development, Commercialization and Supply Agreements

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Development, Commercialization and Supply Agreements

(8) Development, Commercialization and Supply Agreements

In-licenses

Mochida Pharmaceutical Co., Ltd.

In June 2018, the Company entered into a collaboration with Mochida Pharmaceutical Co., Ltd., or Mochida, related to the development and commercialization of drug products and indications based on the active pharmaceutical ingredient in VASCEPA, the omega-3 acid, EPA, or eicosapentaenoic acid. Among other terms in the agreement, the Company obtained an exclusive license to certain Mochida intellectual property to advance the Company’s interests in the U.S. and certain other territories and the parties will collaborate to research and develop new products and indications based on EPA for the Company’s commercialization in the U.S. and certain other territories. The potential new product and indication opportunities contemplated under this agreement are currently in early stages of development.

Upon closing of the collaboration agreement, the Company made a non-refundable, non-creditable upfront payment of approximately $2.7 million. In addition, the agreement provides for the Company to pay milestone payments upon the achievement of certain product development milestones and royalties on net sales of future products arising from the collaboration, if any.

In February 2025 and January 2024, the Company exercised certain rights under the agreement, resulting in payments of $1.0 million in each of such periods to Mochida, which was recorded as research and development expense in the condensed consolidated statement of operations.

Out-licenses

Eddingpharm (Asia) Macao Commercial Offshore Limited

In February 2015, the Company entered into a Development, Commercialization and Supply Agreement, or the DCS Agreement, with Edding, related to the development and commercialization of VASCEPA in Mainland China, Hong Kong, Macau and Taiwan, or collectively, the China Territory. Under the terms of the DCS Agreement, the Company granted to Edding an exclusive (including as to the Company) license with the right to sublicense development and commercialization of VASCEPA in the China Territory for uses that are currently commercialized and under development by the Company based on the Company’s MARINE, ANCHOR and REDUCE-IT clinical trials of VASCEPA.

Under the DCS Agreement, Edding is solely responsible for development and commercialization activities in the China Territory and associated expenses. The Company provides development assistance and is responsible for supplying finished and later bulk drug product at defined prices under negotiated terms. The Company retains all VASCEPA manufacturing rights. Edding agreed to certain restrictions regarding the commercialization of competitive products globally and the Company agreed to certain restrictions regarding the commercialization of competitive products in the China Territory.

The Company assessed this arrangement in accordance with Topic 606 and concluded that the contract counterparty, Edding, is a customer. The Company identified the following performance obligations at the inception of the DCS Agreement: (1) the exclusive license to develop and commercialize VASCEPA in the China Territory for uses that are currently commercialized and under development by the Company; (2) the obligation to participate in various steering committees; and (3) ongoing development and regulatory assistance. Based on the analysis performed, the Company concluded that the identified performance obligations are not distinct and therefore a combined performance obligation.

The transaction price is comprised of the following upfront payments and milestones:


In thousands
Transaction Price Components	Achieved	Amount
Upfront fee	February 2015	$	15,000
Submission of the CTA for the MARINE indication	March 2016		1,000
Approval of VASCEPA under the MARINE indication	March 2017		5,000
Submission of the CTA for the REDUCE-IT indication	October 2023		3,000
Approval of VASCEPA under the REDUCE-IT indication	June 2024		15,000
Regulatory Development Support	Various		1,081
Total Transaction Price		$	40,081

In addition to the non-refundable upfront and regulatory milestone payments described above, the Company is entitled to receive tiered double-digit percentage royalties on net sales of VASCEPA in the China Territory escalating to the high teens. The achievement of sales-based milestone events occur when annual aggregate net sales of VASCEPA in the China Territory equals or exceeds certain specified thresholds, and range from $5.0 million to $50.0 million, for a total of $120.0 million. Each such milestone payment shall be payable only once regardless of how many times the sales milestone event is achieved. Each such milestone payment is non-refundable and non-creditable against any other milestone payments.

None of the other clinical or regulatory milestones has been included in the transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones, including royalties, will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will reevaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

The Company fully recognized the transaction price as of June 30, 2024.


In thousands	Amount
Licensing revenue recognized during the three months ended March 31, 2025 (1)	$	—
Licensing revenue recognized during the three months ended March 31, 2024 (1)		376
Licensing revenue recognized from contract inception through both March 31, 2025 and December 31, 2024	$	40,081

(1)

The Company recognized net product revenue of nil and $3.4 million for the three months ended March 31, 2025 and 2024, respectively, related to sales to Edding.

Biologix FZCo

In March 2016, the Company entered into an agreement with Biologix FZCo, or Biologix, a company incorporated under the laws of the United Arab Emirates, to register and commercialize VASCEPA in several Middle Eastern and North African countries. Under the terms of the distribution agreement, the Company granted to Biologix a non-exclusive license to use its trademarks in connection with the importation, distribution, promotion, marketing and sale of VASCEPA in the Middle East and North Africa territory. Upon closing of the agreement, the Company received a non-refundable upfront payment, which has been fully recognized as of June 30, 2024. The Company is entitled to receive all payments based on total product sales and pays Biologix a service fee in exchange for its services, whereby the service fee represents a percentage of gross selling price which is subject to a minimum floor price.

The Company received approval of VASCEPA under the MARINE and REDUCE-IT indications in the following countries:


Country	MARINE	REDUCE-IT	Launch Date
Lebanon	March 2018	August 2021	June 2018
United Arab Emirates	July 2018	October 2021	February 2019
Qatar	December 2019	April 2021	May 2022
Bahrain	April 2021	April 2022	September 2023
Kuwait	December 2021	March 2023	September 2023
Saudi Arabia	March 2022	June 2023	September 2023

The Company recognized less than $0.1 million of net product revenue for the three months ended March 31, 2025 and nil for the three months ended March 31, 2024 related to sales to Biologix.

HLS Therapeutics, Inc.

In September 2017, the Company entered into an agreement with HLS Therapeutics, Inc., or HLS, a company incorporated under the laws of Canada, to register, commercialize and distribute VASCEPA in Canada. Under the agreement, HLS is responsible for regulatory and commercialization activities and associated costs. The Company is responsible for providing assistance towards local filings, supplying finished product under negotiated supply terms, maintaining intellectual property, and continuing the development and funding of REDUCE-IT related activities.

The Company assessed this arrangement in accordance with Topic 606 and concluded that the contract counterparty, HLS, is a customer. The Company identified the following performance obligations at the inception of the contract: (1) license to HLS to develop, register, and commercialize VASCEPA in Canada; (2) support general development and regulatory activities; and (3) participate in various steering committees. Based on the analysis performed, the Company concluded that the identified performance obligations in the agreement are not distinct and therefore a combined performance obligation.

The transaction price is comprised of the following upfront payments and milestones:


In thousands
Transaction Price Components	Achieved	Amount
Upfront fee	September 2017	$	5,000
Achievement of the REDUCE-IT trial primary endpoint	September 2018		2,500
Approval from Health Canada	December 2019		2,500
Regulatory exclusivity from the Office of Patented Medicines and Liaison	January 2020		3,800
Total Transaction Price		$	13,800

In addition to the non-refundable upfront and regulatory milestone payments just described, the Company is entitled to receive certain sales-based milestone payments of up to an additional $50.0 million, as well as tiered double-digit royalties on net sales of VASCEPA in Canada. None of the other clinical or regulatory milestones has been included in the transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee’s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur and therefore have also been excluded from the transaction price.

The Company fully recognized the transaction price as of June 30, 2023.

The Company recognized net product revenue of nil and $1.9 million for the three months ended March 31, 2025 and 2024, respectively, related to sales to HLS.

CSL Seqirus

In February 2023, the Company entered into an agreement with CSL Seqirus, or CSL, to secure pricing and reimbursement, commercialize and distribute VAZKEPA in Australia and New Zealand. The Company received an upfront payment of $0.5 million, which was fully recognized during the first quarter of 2023. In October 2024, CSL obtained listing of VAZKEPA on the Pharmaceutical Benefits Scheme, or PBS, in Australia, as a result the Company received a non-refundable $1.2 million milestone payment. In addition to the upfront payment, the Company will be eligible to receive event-related milestone payments of approximately $6.0 million and additional product-related milestone payments of approximately $4.0 million. The Company will be responsible for supplying finished product to CSL Seqirus at a price that is the greater of (i) a fixed transfer price, or (ii) a fixed percentage of the net selling price, as defined in the CSL agreement.

The Company assessed this arrangement in accordance with Topic 606 and concluded that the contract counterparty, CSL, is a customer. The Company identified the following distinct performance obligations at the inception of the contract: an exclusive license

to use its trademarks in connection with the importation, distribution, promotion, marketing and sale of VASCEPA in the Australia and New Zealand territories.

The transaction price includes the $0.5 million upfront consideration as well as the $1.2 million milestone payment received related to the listing of VAZKEPA on the PBS in Australia.. Any consideration related to event-based or product-based milestones will be recognized when the related milestone events occur and therefore have also been excluded from the transaction price. The Company will reevaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

The Company did not recognize any licensing revenue in connection with the CSL agreement during the three months ended March 31, 2025 and 2024.

The Company did not recognize net product revenue related to sales to CSL during the three months ended March 31, 2025 and 2024.

The following table presents changes in the balances of the Company’s contract assets and liabilities during the three months ended March 31, 2025 and 2024:


In thousands	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Three months ended March 31, 2025:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	—	$	—	$	—		$	—

Three months ended March 31, 2024:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	4,850	$	—	$	(401	)	$	4,449

During the three months ended March 31, 2025 and 2024, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods:


In thousands	Three months ended March 31,
Revenue recognized in the period from:	2025		2024
Amounts included in contract liability at the beginning of the period	$	—	$	401

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Total revenue, net	$ 42,017	$ 56,519
Less: Cost of goods sold	16,887	24,615
Gross margin	25,130	31,904
Operating expenses:
Selling, general and administrative	36,573	39,889
Research and development	5,312	5,598
Total operating expenses	41,885	45,487
Operating loss	(16,755)	(13,583)
Interest income, net	2,872	3,383
Other income, net	253	1,545
Loss from operations before taxes	(13,630)	(8,655)
Provision for income taxes	(2,067)	(1,298)
Net loss	$ (15,697)	$ (9,953)
Loss per share:
Basic	$ (0.04)	$ (0.02)
Diluted	$ (0.04)	$ (0.02)
Weighted average shares:
Basic	413,422	410,146
Diluted	413,422	410,146
Product Revenue, Net
Total revenue, net	$ 41,035	$ 55,156
Licensing and Royalty Revenue
Total revenue, net	$ 982	$ 1,363

Development, Commercialization and Supply Agreements - Summary of Transaction Price Comprising Upfront Payments and Milestones (Details) - USD ($) $ in Thousands	1 Months Ended									3 Months Ended
	Jun. 30, 2024	Oct. 31, 2023	Jan. 31, 2020	Dec. 31, 2019	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2017	Mar. 31, 2016	Feb. 28, 2015	Mar. 31, 2025
Edding
License And Collaboration Agreements [Line Items]
Regulatory development support										$ 1,081
Total Trasanction Price										40,081
Edding \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received									$ 15,000
Edding \| Clinical Trial Application \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received								$ 1,000
Edding \| Achievement of REDUCE-IT Trial \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received		$ 3,000
Edding \| VASCEPA \| Achievement of REDUCE-IT Trial
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received	$ 15,000
Edding \| VASCEPA \| Marine \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received							$ 5,000
HLS
License And Collaboration Agreements [Line Items]
Total Trasanction Price										$ 13,800
HLS \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received						$ 5,000
Non-refundable milestone payment received			$ 3,800
HLS \| Out-licenses \| Health Canada
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received				$ 2,500
HLS \| Achievement of REDUCE-IT Trial \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received					$ 2,500

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Development, Commercialization and Supply Agreements (Tables)

3 Months Ended

Mar. 31, 2025

License And Collaboration Agreements [Line Items]

Changes in Balances of Contract Assets and Liabilities and Revenues Recognized

The following table presents changes in the balances of the Company’s contract assets and liabilities during the three months ended March 31, 2025 and 2024:


In thousands	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Three months ended March 31, 2025:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	—	$	—	$	—		$	—

Three months ended March 31, 2024:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	4,850	$	—	$	(401	)	$	4,449


In thousands	Three months ended March 31,
Revenue recognized in the period from:	2025		2024
Amounts included in contract liability at the beginning of the period	$	—	$	401

Equity

3 Months Ended

Mar. 31, 2025

Equity [Abstract]

Equity

(6) Equity

ADSs

On March 12, 2025, the Company announced its intent to effect the ADS Ratio Change on its ADSs from one ADS representing one Ordinary Share, to the new ratio of one ADS representing 20 Ordinary Shares. The effective date of the ADS Ratio Change was April 11, 2025.

During the three months ended March 31, 2025 and 2024, except as described above, the Company did not engage in any transactions involving its Ordinary Shares. Refer to Incentive Equity Awards below for discussions of Ordinary Shares issued as a result of stock option exercises and vesting of restricted stock units, or RSUs.

Incentive Equity Awards

The following table summarizes the aggregate number of stock options and RSUs outstanding under the Amarin Corporation plc 2020 Stock Incentive Plan, or the 2020 Plan, as of March 31, 2025:


	March 31, 2025
Outstanding stock options		30,373,266
% of outstanding on a fully-diluted basis		7	%
Outstanding RSUs		19,716,149
% of outstanding on a fully-diluted basis		5	%

The following table represents equity awards activity during the three months ended March 31, 2025 and 2024:


	Three months ended March 31,
	2025		2024
Ordinary Shares issued for stock option exercises		—		9,500
Gross and net proceeds from stock option exercises	$	—	$	10,260
Ordinary Shares issued in settlement of vested RSUs		4,328,179		2,651,407
Ordinary Shares retained for settlement of employee tax obligations ─ RSUs		1,687,443		990,070
Ordinary Shares issued in settlement of vested Performance-based RSUs (1)		257,500		468,230
Ordinary Shares retained for settlement of employee tax obligations ─ Performance-based RSUs		117,898		227,380

(1)

Performance-based RSUs vested in connection with the achievement of certain performance conditions during the year.

In January 2025, the Company granted a total of 10,646,844 RSUs and 3,313,059 stock options to employees under the 2020 Plan. The RSUs and stock options vest 50% on both January 1, 2026 and July 1, 2026, respectively.

In February 2024, the Company granted a total of 6,800,500 RSUs and 2,662,000 stock options to employees under the 2020 Plan. The RSUs vest annually over a three-year period and the stock options vest quarterly over a four-year period with a one-year cliff vesting.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Inventory (Tables)

3 Months Ended

Mar. 31, 2025

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories as of March 31, 2025 and December 31, 2024 consist of the following:


In thousands	March 31, 2025		December 31, 2024
Raw materials	$	83,236	$	91,421
Work in process		29,513		30,482
Finished goods		104,145		108,885
Total inventory 1	$	216,894	$	230,788

Development, Commercialization and Supply Agreements - Summary of Product Approval (Details) - Out-licenses - Biologix [Member] - VASCEPA [Member]	3 Months Ended
	Mar. 31, 2025
Lebanon
License And Collaboration Agreements [Line Items]
Launch Date	2018-06
United Arab Emirates
License And Collaboration Agreements [Line Items]
Launch Date	2019-02
Qatar
License And Collaboration Agreements [Line Items]
Launch Date	2022-05
Bahrain
License And Collaboration Agreements [Line Items]
Launch Date	2023-09
Kuwait
License And Collaboration Agreements [Line Items]
Launch Date	2023-09
Saudi Arabia
License And Collaboration Agreements [Line Items]
Launch Date	2023-09
Marine \| Lebanon
License And Collaboration Agreements [Line Items]
Approval Date	2018-03
Marine \| United Arab Emirates
License And Collaboration Agreements [Line Items]
Approval Date	2018-07
Marine \| Qatar
License And Collaboration Agreements [Line Items]
Approval Date	2019-12
Marine \| Bahrain
License And Collaboration Agreements [Line Items]
Approval Date	2021-04
Marine \| Kuwait
License And Collaboration Agreements [Line Items]
Approval Date	2021-12
Marine \| Saudi Arabia
License And Collaboration Agreements [Line Items]
Approval Date	2022-03
REDUCE-IT \| Lebanon
License And Collaboration Agreements [Line Items]
Launch Date	2021-08
REDUCE-IT \| United Arab Emirates
License And Collaboration Agreements [Line Items]
Launch Date	2021-10
REDUCE-IT \| Qatar
License And Collaboration Agreements [Line Items]
Launch Date	2021-04
REDUCE-IT \| Bahrain
License And Collaboration Agreements [Line Items]
Launch Date	2022-04
REDUCE-IT \| Kuwait
License And Collaboration Agreements [Line Items]
Launch Date	2023-03
REDUCE-IT \| Saudi Arabia
License And Collaboration Agreements [Line Items]
Launch Date	2023-06